BrainChild Bio
brainchildbio.com
Actively hiring
Oncology Therapeutics
Cell & Gene Therapy
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$116M
1 round on record
Latest round
$116M
Series A · Sep 2026 · this month
Team
40
US Form 5500 (plan participants) · Dec 2025 · +18% in a year
Hiring now
6
+1 posted in 30 days
The money's age
Fresh money
0 months since the last round · and hiring
Momentum
42/100
hiring for its size, in the news, fresh money
Last sign of life
this month
a posting or a news item
Tractionpublic signals, read monthly
Web presence
top 7%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Sep 2026 | $116M | — | Chemical & Engineering News |
Similar startupsby what they do, their industry and backers
Learn about Lyell and how we are building an industry-leading clinical-stage pipeline of CAR-T cell product candidates for cancer.
Generate the optimized scFvs to yield CAR-T cells with robust anti-tumor effect.
The Next Generation in. OncoSenX is a late stage pre-clinical cancer company headquartered in Seattle, Washington. OncoSenX targets solid…
Autolus is a CAR T cell therapy company which develops advanced autologous T cell therapies that have the potential to deliver…
Redefining Complement Therapies. Complement Therapeutics is a clinical-stage biotechnology company advancing precision therapies for…
Revolutionizing solid tumor treatment through AI-powered protein engineering. OUTSMART™, OUTLAST™, and OUTSPACER™ technologies enhance…
News
Seattle biotech BrainChild Bio raises $116M to advance CAR T therapy for childhood brain cancer
Seattle biotech BrainChild Bio has raised $116 million to advance an experimental CAR T cell therapy for DIPG, a rare and deadly brain tumor that primarily affects young children. The company is building on technology developed at Seattle Children's and i
Read more
Report
BrainChild Bio Raises $116 Million Series A And Launches Pivotal Phase 2 CAR T Cell Trial For Pediatric Brain Cancer
BrainChild Bio has raised $116 million in Series A funding to advance its CAR T cell therapies for central nervous system tumors, including a pivotal Phase 2 clinical trial of its lead candidate BCB-276 in diffuse intrinsic pontine glioma. The financing w
Read more
Report
BrainChild Bio Initiates Pivotal Phase 2 Trial for BCB-276 CAR T cell Therapy for DIPG, a Deadly Pediatric Brain Cancer
ILLUMINATE Phase 2 pivotal study will enroll patients at six leading pediatric oncology centers across the U.S.B7-H3-targeted autologous CAR T cel...
Read more
Report
BrainChild Bio targets deadly brain cancer in children with $116M series A
BrainChild Bio's lead asset BCB-276 is in pivotal development for diffuse intrinsic pontine glioma, a rare and fatal brain tumor that affects around 300 children in the U.S. every year.
Read more
Report
BrainChild Bio raises over $100 million to treat kids' cancers with CAR-Ts
Cash will be used for a Phase 2 trial of the company's treatment for diffuse intrinsic pontine glioma
Read more
Report
Pro access
Upgrade to see all 8 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Tech stack
Technologies named in job postings at BrainChild Bio over the last 12 months, by layer, with the share of postings for each.
Technologies in use
1
Postings analysed
2
Stack modernity
64/100
Cloud & platforms
GCP
Sign in to see how your skills match this stack
Sign In
Salary insights
Compensation ranges based on this company's open jobs
Median
$168k
Typical range
$115k – $210k
Open positions
4
4
Jobs
Middle
25%
Senior
50%
Architect
25%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Middle | 1 | $115k | $115k |
| Senior | 2 | $168k | $155k – $180k |
| Architect | 1 | $210k | $210k |
Highest paying role
Director, CMC Quality
$210k
Normalized to USD per year
Growth
Hiring Momentum
28/100
Slowing
Open positions
6
0 opened / 0 closed in 30 days
ATS activity
Every ~16 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Operations
33% ▲
Public Policy
17% ▼
Science & Research
17% ▼
Industrial Engineering
17% ▼
Early Careers
17% ▲
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Seattle
Seattle
United States
Support & operations
Contact Us
3 open roles 3 posted in 90 days 50-200 est. staff $150k Avg Salary
hires for Operations, Industrial Engineering
1150 Eastlake Ave, Ste 900, Seattle, WA 98109
Financials
Total raised
$116M
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2026 | $116M | Details |